ClinicalTrials.gg
CompletedNCT05432154Updated Aug 24, 2022

An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis

An interventional study of Film forming silicone gel (7-0940) in Atrophic Vaginitis, sponsored by Stratpharma AG. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2022-08-24.

Sponsored by Stratpharma AG · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 3 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 23 studies in Atrophic Vaginitis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Atrophic Vaginitis · United States.

Enrollment
23rd of 23
10 · median 69
Started
2022
the only one that year
No phase
4 of 23
1 open now
Registered
20th of 23
by date
Lead sponsor
3 of 23
Stratpharma AG

Among the 23 studies in Atrophic Vaginitis with a site in United States, this one is the 23rd largest by enrollment, is the only one that started in 2022, is one of 4 with no phase, and was the 20th registered.

By phase

23 studies; the count open now beside each. This study's row is marked.

Phase 311 · 0 open
Phase 45 · 1 open
No phasethis study4 · 1 open
Phase 12 · 0 open
Phase 1/21 · 0 open

By the year they started

First in 2005; this study’s year is marked. 1 started in 2022.

Size and results

Median enrollment 69 across the 23 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 23 studies in Atrophic Vaginitis with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to determine the efficacy of 7-0940 in the management of atrophic vaginitis in female patients

03

Conditions studied

  • Atrophic Vaginitis

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide
  • Diagnosed acute or chronic Atrophic Vaginitis
  • Controlled disease, or uncontrolled disease that did not respond to standard therapy with HRT

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Patient unable to apply topical device
  • Allergy or intolerance to ingredients or of the formulation of studied products
  • Currently on HRT (orally or topically)
  • Currently on treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Treatment arm

    Patients apply 7-0940 at least 2 times daily for 3 months.

    Device: Film forming silicone gel (7-0940)

Interventions

  • DeviceFilm forming silicone gel (7-0940)

    Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas. Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel. Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue. Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances.

06

What researchers measure

Primary outcomes

  1. Patient-reported Vulvar Quality of Life

    Vulvar Quality of Life Index

    Time frame: 3 months

Secondary outcomes

  1. Patient-reported symptoms

    Likert scales to measure: * Pruritus/itchiness * Tender/sore * Swelling * Dryness * Burning of skin * Dyspareunia * Stinging with urination/clothes * Defecating pain/burning

    Time frame: 3 months

  2. Severity of overall condition

    Clinician-rated severity of atrophic vaginitis

    Time frame: 3 months

  3. Product rating

    Likert scale for product rating by the patient

    Time frame: 3 months

07

Study locations

1 site
  • Orange Coast Women's Medical Group
    Laguna Hills, California 92653, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jul 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2022
First posted
Jun 27, 2022
StartActual
Apr 1, 2022
Primary completionActual
Jul 31, 2022
CompletionActual
Jul 31, 2022
Last update
Aug 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05432154
Lead sponsor
Stratpharma AG
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Apr 1, 2022
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Aug 24, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion